The forecasted sales of cardiovascular system medicines in Norway for the years 2024 through 2028 show a slight decline. In 2023, the market stood at 5.4% of total sales. This percentage then drops to 5.3% in 2024 and 2025, further decreasing to 5.2% in 2026 and 2027, and finally to 5.1% in 2028. The year-on-year variation between 2023 and 2024 is -1.85%, and the same rate is observed between 2024 and 2025. The Compound Annual Growth Rate (CAGR) indicates an average annual decrease of approximately -1.41% over the last five years.
- 2023 to 2024: -1.85%
- 2024 to 2025: -1.85%
- 2025 to 2026: -1.89%
- 2026 to 2027: -1.92%
- 2027 to 2028: -1.92%
- 2023 to 2028 CAGR: -1.41%
Future trends to watch include potential advancements in cardiovascular treatments and technologies, policy changes affecting pharmaceutical pricing, and shifting demographics that may alter demand for cardiovascular medicines. Additionally, monitoring the economic climate and its impact on healthcare budgets will be essential for understanding long-term market conditions.
